[go: up one dir, main page]

MX2018002699A - Piridinona dicarboxamida para uso como inhibidores de bromodominio. - Google Patents

Piridinona dicarboxamida para uso como inhibidores de bromodominio.

Info

Publication number
MX2018002699A
MX2018002699A MX2018002699A MX2018002699A MX2018002699A MX 2018002699 A MX2018002699 A MX 2018002699A MX 2018002699 A MX2018002699 A MX 2018002699A MX 2018002699 A MX2018002699 A MX 2018002699A MX 2018002699 A MX2018002699 A MX 2018002699A
Authority
MX
Mexico
Prior art keywords
piridinone
bromodominum
dicarboxamide
inhibitors
compounds
Prior art date
Application number
MX2018002699A
Other languages
English (en)
Other versions
MX384798B (es
Inventor
Hubert Demont Emmanuel
John Atkinson Stephen
Andrew Harrison Lee
Thomas Seal Jonathan
Elizabeth Aylott Helen
William James COPPER Anthony
George Christopher Hayhow Thomas
J Lindon Matthew
g preston Alexander
David Wall Ian
J Watson Robert
Michael Woolven James
Original Assignee
Glaxosmithkline Ip No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip No 2 Ltd filed Critical Glaxosmithkline Ip No 2 Ltd
Publication of MX2018002699A publication Critical patent/MX2018002699A/es
Publication of MX384798B publication Critical patent/MX384798B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a compuestos de fórmula (I) y sales de los mismos, a composiciones farmacéuticas que contienen tales compuestos y a su uso en terapia (ver Fórmula).
MX2018002699A 2015-09-02 2016-08-31 Piridinona dicarboxamida para uso como inhibidores de bromodominio. MX384798B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562213137P 2015-09-02 2015-09-02
PCT/EP2016/070519 WO2017037116A1 (en) 2015-09-02 2016-08-31 Pyridinone dicarboxamide for use as bromodomain inhibitors

Publications (2)

Publication Number Publication Date
MX2018002699A true MX2018002699A (es) 2018-04-13
MX384798B MX384798B (es) 2025-03-14

Family

ID=56943472

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018002699A MX384798B (es) 2015-09-02 2016-08-31 Piridinona dicarboxamida para uso como inhibidores de bromodominio.

Country Status (22)

Country Link
US (2) US10428026B2 (es)
EP (1) EP3344615A1 (es)
JP (1) JP6532599B2 (es)
KR (1) KR102088157B1 (es)
CN (1) CN108137542B (es)
AR (1) AR105875A1 (es)
AU (1) AU2016315360B2 (es)
CA (1) CA2996245C (es)
CL (1) CL2018000565A1 (es)
CO (1) CO2018002211A2 (es)
CR (1) CR20180138A (es)
DO (1) DOP2018000062A (es)
EA (1) EA033679B1 (es)
HK (1) HK1249504A1 (es)
IL (1) IL257431B (es)
MA (1) MA43940A (es)
MX (1) MX384798B (es)
PE (1) PE20181273A1 (es)
PH (1) PH12018500446A1 (es)
TW (1) TWI724022B (es)
UY (1) UY36875A (es)
WO (1) WO2017037116A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY36875A (es) 2015-09-02 2017-03-31 Glaxosmithkline Intellectual Property (No 2) Ltd Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
AU2016326864A1 (en) 2015-09-22 2018-03-22 Glaxosmithkline Intellectual Property (No.2) Limited Pyridinone dicarboxamide for use as bromodomain inhibitors
US10471050B2 (en) 2015-10-05 2019-11-12 Glaxosmithkline Intellectual Property (No.2) Limited 2-OXO-1,2-dihydropyridine-3,5-dicarboxamide compounds as bromodomain inhibitors
CA3018358A1 (en) 2016-04-07 2017-10-12 Glaxosmithkline Intellectual Property (No.2) Limited Pyridyl derivatives as bromodomain inhibitors
WO2017202742A1 (en) * 2016-05-24 2017-11-30 Glaxosmithkline Intellectual Property (No.2) Limited Pyridine dicarboxamide derivatives as bromodomain inhibitors
GB201703282D0 (en) 2017-03-01 2017-04-12 Glaxosmithkline Intellectual Property (No 2) Ltd Compounds
JOP20190192A1 (ar) 2017-03-01 2019-08-08 Glaxosmithkline Ip No 2 Ltd مشتقات بيرازول بوصفها مثبطات برومودومين
CN108003085A (zh) * 2017-12-19 2018-05-08 张开良 一种药物中间体芳甲酰基吲哚衍生物的合成方法
CN108484494B (zh) * 2018-06-15 2021-07-30 沈阳药科大学 2-氧代-1,2-二氢吡啶-4-甲酸类化合物
GB201814167D0 (en) 2018-08-31 2018-10-17 Glaxosmithkline Ip No 2 Ltd Compounds
JP2023532233A (ja) 2020-06-23 2023-07-27 ジェネンテック， インコーポレイテッド 大環状化合物及びその使用方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100575345C (zh) * 2000-12-28 2009-12-30 盐野义制药株式会社 对2型大麻素受体具有结合活性的吡啶酮衍生物
WO2003070277A1 (en) 2002-02-19 2003-08-28 Shionogi & Co., Ltd. Antipruritics
US7629347B2 (en) 2002-10-09 2009-12-08 Critical Outcome Technologies, Inc. Protein tyrosine kinase inhibitors
ATE469886T1 (de) 2002-11-18 2010-06-15 Schering Corp 17beta-hydroxysteroid dehydrogenase typ-3 hemmer zur behandlung von androgen abhängigen erkrankungen
EP1433788A1 (en) 2002-12-23 2004-06-30 Aventis Pharma Deutschland GmbH Pyrazole-derivatives as factor Xa inhibitors
SE0302487D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
TW200700392A (en) 2005-03-16 2007-01-01 Astrazeneca Ab Novel compounds
TW200808763A (en) 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds I
US8268827B2 (en) * 2007-11-15 2012-09-18 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa. Pyridazinone derivatives as PARP inhibitors
WO2009158315A1 (en) * 2008-06-25 2009-12-30 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
GB0919434D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
UA111756C2 (uk) 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
SG11201408324QA (en) 2012-06-12 2015-01-29 Abbvie Inc Pyridinone and pyridazinone derivatives
AU2013341200A1 (en) 2012-11-08 2015-07-02 Bristol-Myers Squibb Company Heteroaryl substituted pyridyl compounds useful as kinase modulators
WO2014096965A2 (en) 2012-12-21 2014-06-26 Rvx Therapeutics Inc. Novel heterocyclic compounds as bromodomain inhibitors
CN105593224B (zh) 2013-07-31 2021-05-25 恒元生物医药科技(苏州)有限公司 作为溴结构域抑制剂的新型喹唑啉酮类化合物
DE102013215912B3 (de) * 2013-08-12 2015-02-26 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Farbneutral beschichteter kupferhaltiger Gegenstand, Verfahren zu dessen Herstellung sowie Verwendung einer entsprechenden farbneutralen Beschichtung
US9428514B2 (en) 2013-12-09 2016-08-30 Abbvie Inc. Bromodomain inhibitors
AR105646A1 (es) 2015-08-11 2017-10-25 Actelion Pharmaceuticals Ltd Agentes antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona sustituida
UY36875A (es) 2015-09-02 2017-03-31 Glaxosmithkline Intellectual Property (No 2) Ltd Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
US10471050B2 (en) 2015-10-05 2019-11-12 Glaxosmithkline Intellectual Property (No.2) Limited 2-OXO-1,2-dihydropyridine-3,5-dicarboxamide compounds as bromodomain inhibitors
CA3018358A1 (en) 2016-04-07 2017-10-12 Glaxosmithkline Intellectual Property (No.2) Limited Pyridyl derivatives as bromodomain inhibitors
WO2017202742A1 (en) 2016-05-24 2017-11-30 Glaxosmithkline Intellectual Property (No.2) Limited Pyridine dicarboxamide derivatives as bromodomain inhibitors

Also Published As

Publication number Publication date
BR112018003827A2 (en) 2018-09-25
US20190359572A1 (en) 2019-11-28
CN108137542B (zh) 2023-10-27
JP2018526383A (ja) 2018-09-13
UY36875A (es) 2017-03-31
JP6532599B2 (ja) 2019-06-19
EA033679B1 (ru) 2019-11-15
CA2996245C (en) 2023-10-17
IL257431A (en) 2018-04-30
PE20181273A1 (es) 2018-08-03
MA43940A (fr) 2018-12-12
IL257431B (en) 2021-04-29
WO2017037116A1 (en) 2017-03-09
HK1249504A1 (zh) 2018-11-02
CR20180138A (es) 2018-07-16
CL2018000565A1 (es) 2018-07-06
DOP2018000062A (es) 2018-03-30
TW201718504A (zh) 2017-06-01
TWI724022B (zh) 2021-04-11
AR105875A1 (es) 2017-11-15
US10927080B2 (en) 2021-02-23
MX384798B (es) 2025-03-14
EA201890331A1 (ru) 2018-08-31
US10428026B2 (en) 2019-10-01
EP3344615A1 (en) 2018-07-11
US20180258044A1 (en) 2018-09-13
AU2016315360B2 (en) 2019-09-12
KR102088157B1 (ko) 2020-03-12
KR20180043366A (ko) 2018-04-27
PH12018500446A1 (en) 2018-09-10
AU2016315360A1 (en) 2018-03-22
CN108137542A (zh) 2018-06-08
CO2018002211A2 (es) 2018-05-21
CA2996245A1 (en) 2017-03-09

Similar Documents

Publication Publication Date Title
DOP2018000062A (es) Piridinona dicaboxamidas para uso como inhibidores de bromodominio
MX2018008052A (es) Inhibidores de desmetilasa especifica de lisina 1 (lsd1).
SV2017005514A (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
UY35590A (es) Nuevos compuestos para el tratamiento del cáncer
UY35467A (es) Compuestos orgánicos
DOP2017000298A (es) Reguladores de nrf2
DOP2015000270A (es) Potenciador de inhibidores del homólogo de zeste
CU20160052A7 (es) Amino-heteroaril-benzamidas como inhibidores de cinasa
MX2015012456A (es) Compuestos heterociclicos y usos de los mismos.
GT201400196A (es) Compuestos de heterociclilo
CL2014001793A1 (es) Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
CR20160272A (es) REGULADORES DE Nrf2
MX2018005725A (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer.
DOP2014000036A (es) Compuestos de piridazinona y su uso como inhibidores daao
MX2017007377A (es) Compuestos organicos.
MX2017009505A (es) Derivados de 9h-pirrolo-dipiridina.
NI201500096A (es) Compuesto químicos
BR112017002214A2 (pt) composto de fórmula (i), composição farmacêutica e usos de um composto
ECSP17069696A (es) Compuestos novedosos
MX2018002898A (es) Compuestos utiles para inhibir ror-gamma-t.
UY36292A (es) Compuestos de tetrahidroquinolina para su uso como inhibidores de bromodominios
UY37191A (es) Derivados de dibenzofurano para uso como inhibidores de bromodominio
BR112016028017A2 (pt) Inibidor de quinase alk e método de preparação e usos do mesmo
UY36464A (es) Compuestos de quinazolina
CU20150048A7 (es) Compuestos heteroaromáticos como ligandos d1 de dopamina